Total medical devices industry cross border deals worth $4.5bn were announced globally for October 2022, with the $2.6bn acquisition of The Binding Site Group being the sector’s biggest investment, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 401.8% over the previous month of $892.83m and a rise of 57.8% when compared with the last 12-month average of $2.84bn.
In terms of number of cross border deals, the sector saw a drop of 54.69% with 29 deals in October 2022 when compared to the last 12-month average of 64 deals.
In value terms, Europe led the activity with cross border deals worth $3.87bn in October 2022.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMedical Devices industry cross border deals in October 2022: Top deals
The top five cross border deals accounted for 94.5% of the overall value during October 2022.
The combined value of the top five cross border deals stood at $4.24bn, against the overall value of $4.5bn recorded for the month.
The top five medical devices industry cross border deals of October 2022 tracked by GlobalData were:
1) Thermo Fisher Scientific’s $2.6bn acquisition deal with The Binding Site Group
2) The $1.14bn acquisition of M.A. Med Alliance by Cordis
3) Nordic Capital’s $300m private equity deal for 25% stake with Equashield Medical
4) The $100m venture financing of Xunshi Technology by Chende Capital, SoftBank Vision Fund 2, Yiheng Capital Partners, Yuanyi Capital and Zhongwei Capital HoldingLimited
5) KDB Investment’s $100m private equity deal with Think Surgical
